Transient receptor potential channel activation targets multiple stages of the schistosome parasite.

M5493, a novel drug candidate targeting a parasite TRP channel, shows potent activity against multiple stages of Schistosoma mansoni at doses as low as 5 mg/kg in mice.

• Why it matters: Schistosomiasis affects over 250 million people globally and relies on a single drug, praziquantel, raising concerns about drug resistance and the need for alternative treatments that can prevent and treat the disease effectively.
• What they did: Researchers developed M5493, a prodrug targeting a distinct parasite transient receptor potential ion channel, and tested its efficacy in mice infected with S. mansoni, demonstrating robust activity at low doses without sedative side effects.
• The result: M5493’s broad-spectrum efficacy and transmission-blocking potential suggest it could enable single-dose treatments and address limitations of current therapies, aiding in schistosomiasis control efforts.